On August 3, 2026 Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, reported that an abstract was accepted for poster presentation at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 26-30, 2026, in Boston, MA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Aglatimagene besadenovec – Localized Prostate Cancer
Abstract Title: Quantitative Digital Pathology Defines Immune Activation Following Aglatimagene Besadenovec Immunotherapy in Localized Prostate Cancer
Presenter: Francesca Barone, MD, PhD, Chief Scientific Officer, Candel Therapeutics, Needham, MA
Session Title: PQA 06: Genitourinary Cancer, Gynecological Cancer and Health Care Access and Engagement
Session Date/Time: Tuesday, September 29, 2026; 2:15 PM – 3:30 PM ET
Location: Poster Hall – Exhibit Hall A, Thomas M. Menino Convention & Exhibition Center, Boston, MA
(Press release, Candel Therapeutics, AUG 3, 2026, View Source [SID1234669617])